TOP TEN perturbations for 1552362_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552362_a_at
Selected probe(set): 1552362_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552362_a_at (1552362_a_at) across 6622 perturbations tested by GENEVESTIGATOR:

methapyrilene study 7 (330 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample

Relative Expression (log2-ratio):-4.6105394
Number of Samples:4 / 8
Experimental methapyrilene study 7 (330 uM; hES-Heps)
hES-Heps cells exposed to 330 uM methapyrilene (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:
Control vehicle (DMSO) treated hES-Heps cell sample
hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation.

PMA study 8 (0.11 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample

Relative Expression (log2-ratio):-3.986909
Number of Samples:3 / 8
Experimental PMA study 8 (0.11 uM; hES-Heps)
hES-Heps cells exposed to 0.11 uM PMA (dissolved in 0.5% v/v DMSO) for 72 hours. Synonyms: phorbol-12-myristat-13-acetate (PMA), tetradecanoylphorbol-acetate (TPA), tetradecanoyl phorbol acetate, 12-O-tetradecanoylphorbol-13-acetate. Chemical was added at day 22 of differentiation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (DMSO) treated hES-Heps cell sample
hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation.

clonidine study 5 (1615 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample

Relative Expression (log2-ratio):-3.6207685
Number of Samples:3 / 8
Experimental clonidine study 5 (1615 uM; hES-Heps)
hES-Heps cells exposed to 1615 uM clonidine (dissolved in 0.5% v/v DMSO) for 72 hours. Chemical was added at day 22 of differentiation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:, , , ,
Control vehicle (DMSO) treated hES-Heps cell sample
hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation.

azathioprine study 8 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):-3.4904633
Number of Samples:2 / 19
Experimental azathioprine study 8 (48h)
HepG2 cells exposed to 250μM azathioprine in DMSO solvent for 48 hours. ATC code:
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.

hepatocyte-like cell differentiation study 1 (15d) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):3.4168987
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (15d)
Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

paracetamol (acetaminophen) study 7 (10000uM) / vehicle (DMSO) treated HepG2 sample

Relative Expression (log2-ratio):-3.4087172
Number of Samples:3 / 21
Experimental paracetamol (acetaminophen) study 7 (10000uM)
HepG2 cells treated with compound: paracetamol (10000uM; CAS no.:103-90-2) for 24 hours. Paracetamol is hepatotoxic and may cause necrosis. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:
Control vehicle (DMSO) treated HepG2 sample
HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours.

ethinylestradiol study 3 (90uM) / vehicle (DMSO) treated HepG2 sample

Relative Expression (log2-ratio):-3.388978
Number of Samples:3 / 21
Experimental ethinylestradiol study 3 (90uM)
HepG2 cells treated with compound: ethinylestradiol (90uM; CAS no.:57-63-6) for 24 hours. Ethinylestradiol is hepatotoxic and may cause cholestasis. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:,
Control vehicle (DMSO) treated HepG2 sample
HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours.

2-(chloromethyl)pyridine hydrochloride study 1 (24h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):-3.3835812
Number of Samples:3 / 7
Experimental 2-(chloromethyl)pyridine hydrochloride study 1 (24h)
HepG2 cells exposed to 300μM 2-(chloromethyl)pyridine hydrochloride in DMSO solvent for 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 24 hours.

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (15d)

Relative Expression (log2-ratio):-3.280178
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (15d)
Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.

γ-HCH study 1 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):-3.2457
Number of Samples:3 / 19
Experimental γ-HCH study 1 (48h)
HepG2 cells exposed to 2mM lindane (γ-HCH) in DMSO solvent for 48 hours. ATC code:, ,
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.